Open Your Free Demat Account
Enjoy low brokerage on delivery trades
This overview of the Molbio Diagnostics Limited IPO is intended to help investors follow public disclosures under the Bajaj Broking IPO tracker.
Molbio Diagnostics Limited develops point-of-care molecular diagnostic platforms under its Truenat brand, with devices sold in more than 90 countries. The company generated sales of ₹1,445.69 crore in FY2026. The net profit and net worth were at ₹164.14 crore and ₹1,308.78 crore, respectively, for the same year. The RHP highlights the company’s patented technology, recurring revenue from test kits and manufacturing base as commercial strengths.
At the same time, investors may consider reliance on government customers, concentration in TB test kits, and execution risk associated with its R&D pipeline with the RHP’s comprehensive risk disclosures.
India's molecular diagnostics market forms part of a global point-of-care testing (POCT) segment valued at USD 29.3 billion, projected to reach USD 67.1 billion by 2030 at a CAGR of 17.9% (Source: RHP, citing 1Lattice Report). Infectious diseases accounted for approximately 31.0% of global deaths in 2023, underscoring continued demand for rapid diagnostic technology.
Molbio Diagnostics Limited has submitted its Red Herring Prospectus (RHP) to the Securities and Exchange Board of India (SEBI) for raising funds through an initial public offering (IPO). The company manufactures point-of-care diagnostic platforms under its ‘Truenat’ brand used to test for tuberculosis, COVID, Hepatitis B and C, HIV, and other infectious and non-communicable illnesses.
The RHP discloses how the company generates revenue, how it plans to use the issue proceeds, and the risks tied to its operations. This article sets out that information in a structured format.
Molbio Diagnostics IPO details form part of a wider set of Upcoming IPO filings in the diagnostics and healthcare technology space, alongside other IPO listings currently under regulatory review, including the Paras Healthcare Limited IPO.
The table below highlights the key details of the public issue available in the RHP.
| Particulars | Details |
|---|---|
| IPO Type | 100% Book Built Offer |
| IPO Open Date | Mon, Aug 10, 2026 |
| IPO Close Date | Wed, Aug 12, 2026 |
| Face Value | ₹1 per equity share |
| Price Band | ₹768 to ₹807 per share |
| Lot Size | 18 shares |
| Fresh Issue | 24,80,246 shares (agg. up to ₹200 Cr) |
| Offer for Sale | 91,66,000 shares of ₹1 (agg. up to ₹740 Cr) |
| Total Issue Size | 1,16,46,246 shares (agg. up to ₹940 Cr) |
| Listing Exchange | NSE and BSE |
Molbio Diagnostics Limited was originally incorporated as Molbio Diagnostics Private Limited on October 20, 2000, at Panaji, Goa, under the Companies Act, 1956.
The corporate promoters are Sriram Natarajan, Chandrasekhar Bhaskaran Nair, Sangeetha Sriram, Shiva Sriram, Sowmya Sriram and Exxora Trading LLP. As of the RHP filing date, the promoters collectively held 46.65% of the company's pre-Offer paid-up equity share capital.
The company develops point-of-care diagnostic platforms designed for use in resource-limited settings. Its 'Truenat' platform performs real-time PCR testing and is patented in more than 100 countries.
Revenue comes primarily from the sale of Truenat devices and test kits, with test kits generating recurring revenue tied to device installations.
The company's Truenat test chip for tuberculosis diagnosis is the only such rapid molecular test developed by an Indian company and one of only two globally endorsed by the World Health Organization for initial TB diagnosis and rifampicin resistance detection.
The global point-of-care testing market, covering both infectious and non-infectious diseases, stood at USD 29.3 billion as of 2025 and is projected to expand to USD 67.1 billion by 2030, a CAGR of 17.9% (Source: RHP, citing 1Lattice Report). Infectious diseases caused an estimated 19.4 million deaths globally in 2023, close to a third of all deaths that year.
Key growth drivers for the sector include:
Rising demand for decentralised, rapid diagnostic technology
Limited laboratory infrastructure and electricity access in underserved regions
Government and public health programs for infectious disease control
Advancements in portable PCR and molecular testing platforms
Growing screening requirements for non-communicable diseases
Of the estimated 1.5 million global deaths linked to diseases such as TB, hepatitis, and HPV, more than 4,100 deaths occurred daily on average (Source: RHP, citing 1Lattice Report). Molecular diagnostics continue to play a role in early detection and disease monitoring across both public and private healthcare systems.
The financial performance of Molbio Diagnostics Limited over the last three financial years provides insight into its revenue generation, profitability, and balance sheet position. Figures below are drawn from the Restated Financial Statements in the RHP.
| Financials (₹ crore) | FY2026 | FY2025 | FY2024 |
|---|---|---|---|
| Revenue from Operations | 1,445.69 | 1,020.42 | 836.56 |
| EBITDA | 328.24 | 256.64 | 185.09 |
| PAT | 164.14 | 138.58 | 83.54 |
| Total Assets | 2,148.42 | 1,461.56 | 1,221.06 |
| Net Worth | 1,144.68 | 952.95 | 807.94 |
Molbio Diagnostics builds its business on a patented testing platform, a global footprint, and steady investment in research. The points below cover its technology, revenue model, manufacturing base, intellectual property, and management experience, each drawn directly from the RHP's disclosures.
The company's Truenat platform holds patents in more than 100 countries and required 13 years of development to obtain ICMR certification. This regulatory and technical barrier can limit the entry of new competitors into the segment.
The Truenat platform is only used with the company’s disease-specific test kits, creating a recurring revenue for installed devices. This model allows you to see revenue beyond the first device sale.
The company operates six manufacturing facilities in India and a dedicated R&D unit staffed by 153 permanent employees as of March 31, 2026. This infrastructure supports both current production and the company's pipeline of tests under development.
The company has sold over 12,500 devices in more than 90 countries as of March 31, 2026. This distribution footprint can support access to diversified geographies beyond the Indian market.
The company and its Material Subsidiaries hold 16 registered patents, 29 trademarks, 11 designs, and 3 copyrights in India, along with 191 patents in foreign jurisdictions including the United States, China, and Singapore. This portfolio can support the company's position in a research-intensive segment.
The company has expanded into digital imaging and digital pathology through its subsidiaries, Prognosys and OptraScan, and collaborates with other organisations to develop veterinary and enzymatic testing products. This diversification can reduce dependence on the core Truenat platform alone.
The company's Promoter and Chief Executive Officer has over 35 years of experience in diagnostic devices, while the Promoter and Chief Technology Officer has over 33 years of experience in bioprocess modelling. Institutional investors, including an alternate investment fund and an indirect subsidiary of Temasek Holdings, have provided capital and strategic input (Source: RHP).
The company's quality management system is certified under ISO 13485 and MDSAP by TUV SUD Product Service GmbH, in compliance with regulatory criteria set by authorities including India's CDSCO, the European Union, Health Canada, and the U.S. FDA. These certifications can support market access across multiple jurisdictions.
Government and international aid agencies contributed 84.56% of the company's revenue from finished goods in Fiscal 2026. Policy changes or reduced public health funding could affect demand for the company's products.
Revenue from finished goods included 70.20% from TB test kits in Fiscal 2026. A drop in demand for TB testing could impact a large portion of overall revenues.
The top 10 customers accounted for 83.26% of the company's revenue from finished goods in Fiscal 2026. Loss of any of these customers could affect revenue.
Top ten suppliers represented 58.52% of raw material and component purchases in Fiscal 2026. Any supply disruption or rise in input price is a margin risk.
The company continues to spend in R&D to expand its menu of tests, but there is no assurance that new tests will receive regulatory approval or scale commercially. Of the assays targeted for Fiscal 2026, only one was developed and commercialised during the year.
The manufacturing plants, R&D unit and registered office of the company are situated on leasehold land and not owned land. Loss of or inability to renew these leasehold rights could affect operations.
The company’s products have regulatory approval in a number of jurisdictions including the CDSCO of India, U.S. FDA, and health authorities in the European Union and Canada. Any adverse regulatory findings could disrupt operations.
The molecular diagnostics industry is characterised by continuous technological change. The company's ability to develop or adopt new technology on a cost-effective basis will influence its competitive position.
Before evaluating the IPO, investors may consider the following factors:
The company's proprietary Truenat platform and its global regulatory endorsements
Revenue dependence on government and international aid agency customers
Concentration of revenue in tuberculosis test kits
Customer and supplier concentration ratios disclosed in the RHP
R&D pipeline execution and regulatory approval timelines for new tests
Manufacturing capacity utilisation trends across recent fiscals
Dependence on leasehold land for manufacturing and R&D facilities
Growth in profitability and net worth over the reporting periods
Disclaimer :
Investments in securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes. The securities are quoted as an example and not as a recommendation. Past performance is not necessarily a guide to future performance.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and/or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Content Partner - Dalal Street Investment Journal Wealth Advisory Private Limited
This article is for educational purposes only and should not be considered investment advice. Market investments are subject to risks. DSIJ Wealth Advisory Private Limited is a SEBI-registered Research Analyst (Reg. No: INH000006396) and Investment Adviser (Reg. No: INA000001142). Please consult your financial adviser before investing.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Scan the QR to download the Bajaj Broking App for effortless investing and trading